Salivary pepsin for diagnosis of gastro-oesophageal reflux disease in infants (0-18 months) - Salivary pepsin in infants

Academisch Medisch Centrum0 个研究点目标入组 150 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Healthy controls
•- Informed consent signed by caregiver(s)
•- >=34wks gestational age- 24 months postnatal age
•- Negative score in I-GERQ-R questionnaire (<16);Symptomatic infants
•- Informed consent signed by caregiver(s)
•- >=34wks GA - 18 months PNA
•- Attending either a general pediatric outpatient clinic or specific pediatric gastroenterology department for gastro esophageal reflux related symptoms
•- Positive score on I-GERQ-R questionnaire (>=16 points)

•Valid for both healthy subjects and symptomatic infants:
•- Known structural gastro-intestinal abnormalities
•- Previous gastro-intestinal surgery
•- Neurological syndromes and development disorders
•- Any condition that would make it unsafe for the subject to participate determined by the treating physician.
•- Use of anti gastro esophageal reflux medications (prokinetics, erythromycin, proton pump inhibitors, H2 receptor antagonists, antacida) in the last 5 days before inclusion.

发起方